CA3225448A1 - Peptides inhibiteurs du canal calcique 3.2 et leurs utilisations - Google Patents

Peptides inhibiteurs du canal calcique 3.2 et leurs utilisations Download PDF

Info

Publication number
CA3225448A1
CA3225448A1 CA3225448A CA3225448A CA3225448A1 CA 3225448 A1 CA3225448 A1 CA 3225448A1 CA 3225448 A CA3225448 A CA 3225448A CA 3225448 A CA3225448 A CA 3225448A CA 3225448 A1 CA3225448 A1 CA 3225448A1
Authority
CA
Canada
Prior art keywords
aav
inhibitory
pain
type
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3225448A
Other languages
English (en)
Inventor
Quinn H. Hogan
Hongwei Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Wisconsin
Original Assignee
Medical College of Wisconsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin filed Critical Medical College of Wisconsin
Publication of CA3225448A1 publication Critical patent/CA3225448A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Des aspects de la divulgation concernent des constructions comprenant un ou plusieurs polypeptides inhibiteurs de Cav3.2 qui bloquent l'activité des canaux calciques de type T Cav3.2 et l'excitation neuronale du ganglion spinal (DRG) nociceptif. L'invention concerne également des méthodes de traitement de la douleur chez un sujet en ayant besoin. En particulier, l'invention concerne des méthodes comprenant l'administration de constructions peptidiques inhibitrices de Cav3.2 à un ganglion spinal du sujet, l'expression des polypeptides inhibiteurs de Cav3.2 inhibant partiellement ou totalement l'activité du canal calcique de type T Cav3.2 dans le DRG.
CA3225448A 2021-06-29 2022-06-29 Peptides inhibiteurs du canal calcique 3.2 et leurs utilisations Pending CA3225448A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163216032P 2021-06-29 2021-06-29
US63/216,032 2021-06-29
PCT/US2022/035509 WO2023278565A1 (fr) 2021-06-29 2022-06-29 Peptides inhibiteurs du canal calcique 3.2 et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3225448A1 true CA3225448A1 (fr) 2023-01-05

Family

ID=84690623

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3225448A Pending CA3225448A1 (fr) 2021-06-29 2022-06-29 Peptides inhibiteurs du canal calcique 3.2 et leurs utilisations

Country Status (4)

Country Link
US (1) US20230018405A1 (fr)
EP (1) EP4362967A1 (fr)
CA (1) CA3225448A1 (fr)
WO (1) WO2023278565A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2377931A1 (fr) * 1999-07-02 2001-01-11 Neuromed Technologies, Inc. Nouveaux canaux calciques mammiferes et sondes, lignees cellulaires et procedes correspondants
WO2005033139A2 (fr) * 2003-05-28 2005-04-14 Synta Pharmaceuticals Corp. Nouveaux canaux calciques et leurs utilisations
EP1713900A4 (fr) * 2004-01-27 2009-06-17 Compugen Ltd Procedes et systemes pour l'annotation de sequences de biomolecules
EP1730173A4 (fr) * 2004-02-18 2008-10-08 Merck & Co Inc Molecules d'acide nucleique codant de nouvelles proteines murines a canal de calcium active faible tension, 1h alpha specialise, proteines codees et procedes d'utilisation de celles-ci
WO2022217285A1 (fr) * 2021-04-09 2022-10-13 The Trustees Of The University Of Pennsylvania Antibiotiques cachés présents dans le protéome humain

Also Published As

Publication number Publication date
US20230018405A1 (en) 2023-01-19
WO2023278565A1 (fr) 2023-01-05
EP4362967A1 (fr) 2024-05-08

Similar Documents

Publication Publication Date Title
AU2018262281B2 (en) Self-inactivating viral vector
AU2016344508A1 (en) Genetic construct
JP7170656B2 (ja) Ｍｅｃｐ２ベースの治療
JP2022110004A (ja) 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療
WO2016106458A1 (fr) Virus aav/xbp1s-ha, procédé de traitement génétique et utilisation de celui-ci pour l'optimisation et l'amélioration des capacités cognitives, de la mémoire et de l'apprentissage
KR20200005549A (ko) 신경퇴행성 장애 또는 뇌졸중의 치료에서 사용하기 위한 유전자 작제물
WO2015044704A1 (fr) Utilisation d'un agoniste de neuroglobuline pour prévenir ou traiter des maladies mitochondriales dues à une déficience de rcciii et/ou rcci
US20180161395A1 (en) Methods and pharmaceutical composition for the treatment of alzheimer's disease
US20240016889A1 (en) Compositions and methods for treating motor neuron diseases
US20230018405A1 (en) Calcium Channel 3.2 Inhibitory Peptides and Uses Thereof
WO2017075729A1 (fr) Virus aav/upr-plus, protéine de fusion upr-plus, méthode de traitement génétique et son utilisation dans le traitement de maladies neurodégénératives telles que, entre autres, la maladie de parkinson et la maladie de huntington
Morrissey et al. The tripeptide RER mimics secreted amyloid precursor protein-alpha in upregulating LTP
CA2977464C (fr) Therapie genique pour ameliorer la vision
US11241478B2 (en) Adenovirus-associated viral vectors for expressing variants of tetratricopeptide repeat (TPR)-containing Rab8b interacting (TRIP8b) protein in neurons and uses thereof for treating major depressive disorder (MDD)
US20190309026A1 (en) Compositions and Methods for Altering Amyloid Precursor Protein (APP) Processing
WO2024178151A2 (fr) Peptides kibra et leurs utilisations
KR20240023127A (ko) 망막 장애
US20200093890A1 (en) Compositions and methods for treating alzheimer's disease
KR20230148207A (ko) 안구 병태에 대한 바이러스 벡터-기반 유전자 요법
CN117813321A (zh) 视网膜病症
US8546348B2 (en) Upregulation of opioid receptors for management